BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rodrigues DA, Roe A, Griffith D, Chonghaile TN. Advances in the Design and Development of PROTAC-mediated HDAC degradation. Curr Top Med Chem 2021. [PMID: 34649488 DOI: 10.2174/1568026621666211015092047] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Sobko A. Cell biologist’s perspective: frontiers in the development of PROTAC-HDAC degraders. JSRT 2022;7:40-45. [DOI: 10.15406/jsrt.2022.07.00155] [Reference Citation Analysis]
2 Li Y, Lin S, Gu Z, Chen L, He B. Zinc-dependent deacetylases (HDACs) as potential targets for treating Alzheimer’s disease. Bioorganic & Medicinal Chemistry Letters 2022;76:129015. [DOI: 10.1016/j.bmcl.2022.129015] [Reference Citation Analysis]
3 Macabuag N, Esmieu W, Breccia P, Jarvis R, Blackaby W, Lazari O, Urbonas L, Eznarriaga M, Williams R, Strijbosch A, Van de Bospoort R, Matthews K, Clissold C, Ladduwahetty T, Vater H, Heaphy P, Stafford DG, Wang HJ, Mangette JE, McAllister G, Beaumont V, Vogt TF, Wilkinson HA, Doherty EM, Dominguez C. Developing HDAC4-Selective Protein Degraders To Investigate the Role of HDAC4 in Huntington's Disease Pathology. J Med Chem 2022. [PMID: 36098485 DOI: 10.1021/acs.jmedchem.2c01149] [Reference Citation Analysis]